Ovid Therapeutics (NASDAQ:OVID) Shares Down 6.1% on Disappointing Earnings

Ovid Therapeutics (NASDAQ:OVID – Get Free Report)’s share price dropped 6.1% on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $2.65 and last traded at $2.6750. Approximately 350,608 shares traded hands during trading, a decline of 85% from the average session volume of 2,305,716 shares. The stock had previously closed at $2.85.

The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02).

Analyst Ratings Changes

Several research firms recently commented on OVID. Roth Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Ovid Therapeutics in a report on Thursday, September 3rd. UBS Group reissued a “buy” rating on shares of Ovid Therapeutics in a research report on Friday, September 11th. Wolfe Research began coverage on shares of Ovid Therapeutics in a research note on Thursday, October 15th. They set an “outperform” rating and a $5.00 target price on the stock. Wall Street Zen raised shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Guggenheim initiated coverage on shares of Ovid Therapeutics in a research note on Tuesday, October 6th. They issued a “buy” rating and a $7.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.00.

View Our Latest Stock Analysis on Ovid Therapeutics

Hedge Funds Weigh In On Ovid Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of OVID. Jupiter Topco LLC bought a new stake in shares of Ovid Therapeutics in the second quarter worth $55,898,000. BlackRock Inc. purchased a new stake in Ovid Therapeutics during the second quarter valued at $29,115,000. Janus Henderson Group PLC bought a new position in Ovid Therapeutics in the first quarter valued at about $23,732,000. ADAR1 Capital Management LLC bought a new position in Ovid Therapeutics in the second quarter valued at about $19,953,000. Finally, Braidwell LP bought a new position in Ovid Therapeutics in the second quarter valued at about $15,923,000. 72.24% of the stock is owned by institutional investors.

Ovid Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 12.39 and a quick ratio of 12.39. The firm has a 50-day simple moving average of $2.52 and a 200-day simple moving average of $2.39.

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

Further Reading

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.